Picture of Biovica International AB logo

BIOVIC B — Biovica International AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+9.25%
3m+32.97%
6m+20.23%
1yr-14.84%
Volume Change (%)
10d/3m-20.77%
Price vs... (%)
52w High-48.12%
50d MA+6.67%
200d MA-5.78%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-36.97%
Return on Equity-31.36%
Operating Margin-4148.17%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for BIOVIC B

Biovica International Ab (STO:BIOVIC B): buy, sell or hold? background image

Biovica International Ab (STO:BIOVIC B): buy, sell or hold?

Shares in Biovica International Ab (STO:BIOVIC B) are currently trading close to a 52 week high, with the share price up by around 50.5% - to 20.8 - over the past week. On a one-month basis, the Biovica International Ab price has risen...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Apr 202230th Apr 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biovica International AB EPS forecast chart

Profile Summary

Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Directors

Last Annual
April 30th, 2021
Last Interim
January 31st, 2022
Incorporated
December 29th, 2008
Public Since
March 29th, 2017
No. of Employees
25
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
28,488,372

BIOVIC B Share Price Performance

Upcoming Events for BIOVIC B

Q1 2023 Biovica International AB Earnings Release

Biovica International AB Annual Shareholders Meeting

Q2 2023 Biovica International AB Earnings Release

Similar to BIOVIC B

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

FAQ

Or unlock with your email

Or unlock with your email